대한의생명과학회지 (Biomedical Science Letters)

  • 제29권4호
  • /
  • Pages.231-241
  • /
  • 2023
  • /
  • 1738-3226(pISSN)
  • /
  • 2288-7415(eISSN)
대한의생명과학회 (The Korean Society for Biomedical Laboratory Sciences)
권호 표지
DOI QR코드

DOI QR Code

Optimization of Aerosolizable Messenger RNA Lipid Nanoparticles for Pulmonary Delivery

  • Se-Hee Lee (Department of Biomedical Laboratory Science, Konyang University) ;
  • Jong Sam Lee (Department of Bioscience and Biotechnology, Konkuk University) ;
  • Dong-Eun Kim (Department of Bioscience and Biotechnology, Konkuk University) ;
  • Keun-Sik Kim (Department of Biomedical Laboratory Science, Konyang University)
  • 투고 : 2023.11.01
  • 심사 : 2023.12.05
  • 발행 : 2023.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Messenger RNA (mRNA)-based vaccines and treatments have recently emerged as a promising strategy. Naked mRNA presents various limitations for direct delivery. Therefore, in this paper, Lipid Nanoparticles (LNPs) were utilized for the delivery of mRNA. Lipid nanoparticle (LNP) mRNA systems are highly effective as vaccines, but their efficacy for pulmonary delivery has not yet been fully established. Additionally, research on effective delivery systems and administration methods for vaccines is required to resolve the stability and degradation issues associated with naked mRNA delivery. This study aimed to determine mRNA delivery efficiency via the inhalation of a lipid nanoparticle (LNP) formulation designed specifically for pulmonary delivery. To this purpose, we built a library of seven LNP configurations with different lipid molar and N/P ratios and evaluated their encapsulation efficiency using gel retardation assay. Among the tested LNPs, LNP1, LNP2-2, and LNP3-2 demonstrated high transfection efficiency in vitro based on FACS analyses luciferase assays, and intracellular accumulation tests. The mRNA delivery efficiencies of the selected LNPs after inhalation and intravenous injection were compared and evaluated. LNP2-2 showed the highest mRNA expression in healthy mouse lungs when aerosolized and was found to be non-toxic. These results indicate that LNP2-2 is a promising carrier for lung mRNA delivery via inhalation.

키워드

과제정보

This research was funded by grants from the National Research Foundation of Korea (NRF-2021R1F1A1062932). Scheme1 adapted from "Rat Timeline", by BioRender.com (2023). Retrieved from https://app.biorender.com/biorender-templates.

참고문헌

  1. Ahmad A, Khan JM, Haque S. Strategies in the design of endosomolytic agents for facilitating endosomal escape in nanoparticles. Biochimie. 2019. 160: 61-75. https://doi.org/10.1016/j.biochi.2019.02.012
  2. Albertsen CH, Kulkarni JA, Witzigmann D, Lind M, Petersson K, Simonsen JB. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv Drug Deliv Rev. 2022. 188: 114416.
  3. Deng Y, Zhang N, Zhang Y, Zhong X, Xu S, Qiu H, et al. Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters. Cell Res. 2022. 32: 375-382. https://doi.org/10.1038/s41422-022-00630-0
  4. Fukushige K, Tagami T, Naito M, Goto E, Hirai S, Hatayama N, et al. Developing spray-freeze-dried particles containing a hyaluronic acid-coated liposome-protamine-DNA complex for pulmonary inhalation. Int J Pharm. 2020. 583: 119338.
  5. Garbuzenko OB, Mainelis G, Taratula O, Minko T. Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention. Cancer Biology & Medicine. 2014. 11: 44.
  6. Gupta A, Andresen JL, Manan RS, Langer R. Nucleic acid delivery for therapeutic applications. Adv Drug Deliv Rev. 2021. 178: 113834.
  7. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nature Reviews Materials. 2021. 6: 1078-1094. https://doi.org/10.1038/s41578-021-00358-0
  8. Idris A, Davis A, Supramaniam A, Acharya D, Kelly G, Tayyar Y, et al. A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19. Molecular Therapy. 2021. 29: 2219-2226. https://doi.org/10.1016/j.ymthe.2021.05.004
  9. Jayaraman M, Ansell SM, Mui BL, Tam YK, Chen J, Du X, et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angewandte Chemie. 2012. 124: 8657-8661. https://doi.org/10.1002/ange.201203263
  10. Jiang Q, Yi M, Guo Q, Wang C, Wang H, Meng S, et al. Protective effects of polydatin on lipopolysaccharide-induced acute lung injury through TLR4-MyD88-NF-κB pathway. Int Immunopharmacol. 2015. 29: 370-376. https://doi.org/10.1016/j.intimp.2015.10.027
  11. Kenjo E, Hozumi H, Makita Y, Iwabuchi KA, Fujimoto N, Matsumoto S, et al. Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice. Nature Communications. 2021. 12: 7101.
  12. Lee W, Loo C, Ghadiri M, Leong C, Young PM, Traini D. The potential to treat lung cancer via inhalation of repurposed drugs. Adv Drug Deliv Rev. 2018. 133: 107-130. https://doi.org/10.1016/j.addr.2018.08.012
  13. Leong EW, Ge R. Lipid nanoparticles as delivery vehicles for inhaled therapeutics. Biomedicines. 2022. 10: 2179.
  14. Li C, Li T, Huang L, Yang M, Zhu G. Self-assembled Lipid Nanoparticles for Ratiometric Codelivery of Cisplatin and siRNA Targeting XPF to Combat Drug Resistance in Lung Cancer. Chemistry-An Asian Journal. 2019. 14: 1570-1576. https://doi.org/10.1002/asia.201900005
  15. Liang Y, Huang L, Liu T. Development and delivery systems of mRNA vaccines. Frontiers in Bioengineering and Biotechnology. 2021. 9: 718753.
  16. Lokugamage MP, Vanover D, Beyersdorf J, Hatit MZ, Rotolo L, Echeverri ES, et al. Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs. Nature Biomedical Engineering. 2021. 5: 1059-1068. https://doi.org/10.1038/s41551-021-00786-x
  17. Medina-Magues LG, Gergen J, Jasny E, Petsch B, Lopera-Madrid J, Medina-Magues ES, et al. mRNA vaccine protects against zika virus. Vaccines. 2021. 9: 1464.
  18. Miao H, Huang K, Li Y, Li R, Zhou X, Shi J, et al. Optimization of formulation and atomization of lipid nanoparticles for the inhalation of mRNA. Int J Pharm. 2023. 640: 123050.
  19. Pardi N, Hogan MJ, Weissman D. Recent advances in mRNA vaccine technology. Curr Opin Immunol. 2020. 65: 14-20. https://doi.org/10.1016/j.coi.2020.01.008
  20. Perche F, Clemencon R, Schulze K, Ebensen T, Guzman CA, Pichon C. Neutral lipopolyplexes for in vivo delivery of conventional and replicative RNA vaccine. Molecular TherapyNucleic Acids. 2019. 17: 767-775. https://doi.org/10.1016/j.omtn.2019.07.014
  21. Qiu M, Tang Y, Chen J, Muriph R, Ye Z, Huang C, et al. Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis. Proceedings of the National Academy of Sciences. 2022. 119: e2116271119.
  22. Qiu Y, Man RC, Liao Q, Kung KL, Chow MY, Lam JK. Effective mRNA pulmonary delivery by dry powder formulation of PEGylated synthetic KL4 peptide. J Controlled Release. 2019. 314: 102-115. https://doi.org/10.1016/j.jconrel.2019.10.026
  23. Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, et al. Modified mRNA vaccines protect against Zika virus infection. Cell. 2017. 168: 1114-1125. e10. https://doi.org/10.1016/j.cell.2017.02.017
  24. Robinson E, MacDonald KD, Slaughter K, McKinney M, Patel S, Sun C, et al. Lipid nanoparticle-delivered chemically modified mRNA restores chloride secretion in cystic fibrosis. Molecular Therapy. 2018. 26: 2034-2046. https://doi.org/10.1016/j.ymthe.2018.05.014
  25. Rosenblum D, Gutkin A, Kedmi R, Ramishetti S, Veiga N, Jacobi AM, et al. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Science advances. 2020. 6: eabc9450.
  26. Rybakova Y, Kowalski PS, Huang Y, Gonzalez JT, Heartlein MW, DeRosa F, et al. mRNA delivery for therapeutic anti-HER2 antibody expression in vivo. Molecular Therapy. 2019. 27: 1415-1423. https://doi.org/10.1016/j.ymthe.2019.05.012
  27. Shen Y, Sun Z, Guo X. Citral inhibits lipopolysaccharide-induced acute lung injury by activating PPAR-γ. Eur J Pharmacol. 2015. 747: 45-51. https://doi.org/10.1016/j.ejphar.2014.09.040
  28. Supramaniam A, Tayyar Y, Clarke DT, Kelly G, Morris KV, McMillan NA, et al. Intranasal delivery of lipid nanoparticle encapsulated SARS-CoV-2 and RSV-targeting siRNAs reduces lung infection. bioRxiv. 2022. 2022.07. 25: 501479.
  29. Tam A, Kulkarni J, An K, Li L, Dorscheid DR, Singhera GK, et al. Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways. European Journal of Pharmaceutical Sciences. 2022. 176: 106234.
  30. Vlatkovic I. Non-immunotherapy application of LNP-mRNA: maximizing efficacy and safety. Biomedicines. 2021. 9: 530.
  31. Wang Z, Ma W, Fu X, Qi Y, Zhao Y, Zhang S. Development and applications of mRNA treatment based on lipid nanoparticles. Biotechnol Adv. 2023: 108130.
  32. Xu X, Xie Q, Shen Y, Lu G, Yao H, Chen Y, et al. Involvement of mannose receptor in the preventive effects of mannose in lipopolysaccharide-induced acute lung injury. Eur J Pharmacol. 2010. 641: 229-237. https://doi.org/10.1016/j.ejphar.2010.05.021
  33. Ye Q, Wu M, Zhou C, Lu X, Huang B, Zhang N, et al. Rational development of a combined mRNA vaccine against COVID19 and influenza. NPJ Vaccines. 2022. 7: 84.
  34. Zhang H, Leal J, Soto MR, Smyth HD, Ghosh D. Aerosolizable lipid nanoparticles for pulmonary delivery of mRNA through design of experiments. Pharmaceutics. 2020. 12: 1042.
  35. Zhuang X, Qi Y, Wang M, Yu N, Nan F, Zhang H, et al. mRNA vaccines encoding the HA protein of influenza A H1N1 virus delivered by cationic lipid nanoparticles induce protective immune responses in mice. Vaccines. 2020. 8: 123.